Printer Friendly

Parkinson's UK launches GBP1m virtual biotech company to create new treatments.

M2 PHARMA-March 9, 2017-Parkinson's UK launches GBP1m virtual biotech company to create new treatments


Parkinson's UK has teamed up with the University of Sheffield to launch a GBP1m virtual biotech company to create new treatments for the disease, the charity announced on Wednesday.

The move is thought to be the first time that a charity has approached a research partner to set up an offshoot company in this way.

The new company, Keapstone Therapeutics, will combine the university's world-leading research with funding and expertise from the charity. This will be channelled to develop new treatments for Parkinson's.

Researchers at the University of Sheffield have already identified small 'drug-like' molecules that can activate a possible in-built defence system to help protect brain cells from oxidative stress - which causes damage to brain tissue and cells, and plays a key role in the disease.

Keapstone Therapeutics will further develop these molecules, which it is hoped could become new drugs to slow or halt the progression of Parkinson's.

Commenting on the partnership, Parkinson's UK's director of research, Arthur Roach, said that the creation of a spinout biotech company would allow it to investigate and develop potential treatments "with an intensity that is unprecedented for a charity".

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUUK
Date:Mar 9, 2017
Previous Article:TiGenix announces topline data for Phase III Crohn's disease study.
Next Article:BioCryst Pharmaceuticals prices public offering at USD8.50 per share.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters